Non-Squamous Non-Small Cell Lung CancerPhase 3OAKNCT02008227
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
A Phase 3 study testing Atezolizumab and Docetaxel in people with Non-Squamous Non-Small Cell Lung Cancer, run by Hoffmann-La Roche at 208 sites in 31 countries.
Trial summary
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-Squamous Non-Small Cell Lung Cancer
- What is being tested?
- Atezolizumab and Docetaxel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,225 participants
- Where
- 208 sitesin 31 countries
- Study dates
- 11 Mar 2014to 9 Jan 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
- Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Who cannot join
- Known active or untreated central nervous system (CNS) metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Active hepatitis B or hepatitis C
- Prior treatment with docetaxel
- Prior treatment with cluster of differentiation 137 (CD137) agonists, anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4), anti-programmed death-1 (anti-PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Trial locations and contacts
208 sites in 31 countries.
208 sites in 31 countries
United States59 sites
Georgia Cancer Specialists
Atlanta, Georgia, 30341
Texas Onc-Central Austin CA Ct
Austin, Texas, 78731
Comprehensive Blood/Cancer Ctr
Bakersfield, California, 93309
Hematology-Oncology; Associates of the Quad Cities
Bettendorf, Iowa, 52722
Billings Clinic; Research Center
Billings, Montana, 59101
Roswell Park Cancer Inst.
Buffalo, New York, 14263
Roy & Patricia Disney Family Cancer Center
Burbank, California, 91505
New York Oncology Hematology PC - Latham
Clifton Park, New York, 12065
Mid Ohio Onc Hematology Inc
Columbus, Ohio, 43219
Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building
Detroit, Michigan, 48201
Willamette Valley Cancer Ctr - 520 Country Club
Eugene, Oregon, 97401-8122
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031
San Juan Oncology Associates
Farmington, New Mexico, 87401
Summit Medical Center
Florham Park, New Jersey, 07932
St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr
Fullerton, California, 92835
St. Mary's Hospital Regional Cancer Center
Grand Junction, Colorado, 81501
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Kaiser Permanente - Hayward
Hayward, California, 94545
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89014
The Methodist Cancer Center
Houston, Texas, 77030
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
Jacksonville, Florida, 32256
Scripps Clinic; Hematology & Oncology
La Jolla, California, 92037-1027
Comprehensive Cancer Centers of Nevada - Eastern Avenue
Las Vegas, Nevada, 89169
Kaiser Permanente - Franklin; Kaiser Permanente - Lone Tree
Lone Tree, Colorado
Pacific Shores Medical Group
Long Beach, California, 90813
Univ of Calif, Los Angeles; Hematology/Oncology
Los Angeles, California, 90095
AMPM Research Clinic
Miami, Florida, 33145
Aurora Health Care; Patient Centered Research
Milwaukee, Wisconsin, 53215
US Oncology Research at Minnesota Oncology
Minneapolis, Minnesota, 55404
University of Minnesota
Minneapolis, Minnesota, 55455
Montana Cancer Specialists
Missoula, Montana, 59802
Virginia Oncology Associates
Norfolk, Virginia, 23502
North Valley Hem Onc Med Grp; Thomas&Dorothy Leavey Can Ctr
Northridge, California, 91328
Kaiser Permanente - Oakland
Oakland, California, 94611
Oncology Hematology West Midwest
Omaha, Nebraska, 68130
Orlando Health Inc.
Orlando, Florida, 32806
Luckow Pavillion, Valley Hosp; Office of Clinical Trials
Paramus, New Jersey, 07652
Illinois Cancer Care
Peoria, Illinois, 61615
Rhode Island Hospital
Providence, Rhode Island, 02903
Quincy Medical Group
Quincy, Illinois, 62301
TMPN/ Cancer Care Associates
Redondo Beach, California, 90277
Blue Ridge Cancer Care
Roanoke, Virginia, 24014
Kaiser Permanente - Roseville
Roseville, California, 95661
Kaiser Permanente Sacramento Medical Center
Sacramento, California, 95814
UC Davis; Comprehensive Cancer Center
Sacramento, California, 95817
Kaiser Permanente - San Francisco (2238 Geary)
San Francisco, California, 94115
K. Permanente - San Jose
San Jose, California, 95119
Coastal Integrative Cancer Care
San Luis Obispo, California, 93401
Kaiser Permanente - San Marcos
San Marcos, California, 92069
K. Permanente - Santa Clara
Santa Clara, California, 95051
Central Coast Medical Oncology
Santa Maria, California, 93454
New England Cancer Specialists
Scarborough, Maine, 04074
K. Permanente - S. San Fran
South San Francisco, California, 94080
Northwest Medical Specialties
Tacoma, Washington, 98405
Cancer Treatment Centers of America-Tulsa
Tulsa, Oklahoma, 74133
Texas Oncology, P.A. - Tyler; Tyler Cancer Center
Tyler, Texas, 75702
Kaiser Permanente - Vallejo
Vallejo, California, 94589
Northwest Cancer Specialists - Vancouver
Vancouver, Washington, 98684
K. Permanente - Walnut Creek
Walnut Creek, California, 94596
France21 sites
Institut Sainte Catherine
Avignon, 84918
Hopital Jean Minjoz; Pneumologie
Besançon, 25030
Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
Bordeaux, 33077
Centre Francois Baclesse
Caen, 14076
Centre Hospitalier Intercommunal; Service de Pneumologie
Créteil, 94010
Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie
Grenoble, 38043
Centre Jean Bernard; Radiotherapie Chimiotherapie
Le Mans, 72000
Centre Oscar Lambret
Lille, 59020
Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique
Marseille, 13915
Hopital Emile Muller;Pneumologie
Mulhouse, 68070
Hopital Cochin; Unite Fonctionnelle D Oncologie
Paris, 75014
Hopital Saint Louis; Oncologie Medicale
Paris, 75475
GH Paris Saint Joseph; Pneumologie
Paris, 75674
Hopital Tenon;Pneumologie
Paris, 75970
Centre Hospitalier Lyon Sud; Pneumologie
Pierre-Bénite, 69495
CH de la region d Annecy
Pringy, 74374
Hopital de Pontchaillou; Service de Pneumologie
Rennes, 35033
Centre Paul Strauss; Oncologie Medicale
Strasbourg, 67065
Hopital Foch; Pneumologie
Suresnes, 92151
Hia Sainte Anne; Pneumologie
Toulon, 83041
Hopital Larrey; Pneumologie
Toulouse, 31059
Italy16 sites
Azienda Ospedaliera San Giuseppe Moscati
Avellino, Campania, 83100
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
Aviano, Friuli Venezia Giulia, 33081
Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
Bari, Apulia, 70124
POLICLINICO RODOLICO, U.O. di Oncologia Medica
Catania, Sicily, 95100
Istituto Nazionale per la Ricerca sul Cancro di Genova
Genoa, Liguria, 16132
Ospedale San Luca; Oncologia
Lucca, Tuscany, 55100
Irccs Ospedale San Raffaele;Oncologia Medica
Milan, Lombardy, 20132
Istituto Europeo Di Oncologia
Milan, Lombardy, 20141
ASST DI MONZA; Oncologia Medica
Monza, Lombardy, 20900
Seconda Universita' Degli Studi; Divsione Di Oncologia Medica
Naples, Campania, 80131
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
Padova, Veneto, 35128
Azienda Ospedaliera Univ Parma; Dept Oncologia Medica
Parma, Emilia-Romagna, 43100
A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii
Pisa, Tuscany, 56124
Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna
Rome, Lazio, 00168
Azienda Ospedaliero-Uni Ria Di Udine; Dept. Di Oncologia - Padiglione Pennato
Udine, Friuli Venezia Giulia, 33100
A.O.U. Integrata Verona - Policlinico G.B. Rossi; Oncologia Medica - Dip. di Medicina
Verona, Veneto, 37134
Japan16 sites
Aichi Cancer Center Hospital; Respiratory Medicine
Aichi, 464-8681
National Cancer Center Hospital East; Thoracic Oncology
Chiba, 277-8577
National Hospital Organization Shikoku Cancer Center; Internal Medicine
Ehime, 791-0280
National Hospital Organization Kyushu Cancer Center, Thoracic Oncology
Fukuoka, 811-1395
Kobe City Medical Center General Hospital; Respiratory Medicine
Hyōgo, 650-0047
Hyogo Cancer Center; Thoracic Oncology
Hyōgo, 673-8558
Miyagi Cancer Center; Respiratory Medicine
Miyagi, 981-1293
Okayama University Hospital; Respiratory and Allergy Medicine
Okayama, 700-8558
Kindai University Hospital; Medical Oncology
Osaka, 589-8511
National Hospital Organization Kinki-Chuo Chest Medical Center; Internal Medicine
Osaka, 591-8555
Saitama Cancer Center; Thoracic Oncology
Saitama, 362-0806
Shizuoka Cancer Center; Thoracic Oncology
Shizuoka, 411-8777
National Cancer Center Hospital; Thoracic Medical Oncology
Tokyo, 104-0045
The Cancer Institute Hospital of JFCR, Respiratory Medicine
Tokyo, 135-8550
Tokyo Medical University Hospital; Dept of Surgery
Tokyo, 160-0023
National Hospital Organization, Yamaguchi - Ube Medical Center; Oncology Medicine
Yamaguchi, 755-0241
Spain10 sites
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
A Coruña, 15006
Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia
Las Palmas de Gran Canaria, LAS Palmas, 35016
Hospital Ramon y Cajal; Servicio de Oncologia
Madrid, 28034
Fundacion Jimenez Diaz; Servicio de Oncologia
Madrid, 28040
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
Madrid, 28040
Hospital Universitario 12 de Octubre; Servicio de Oncologia
Madrid, 28041
Hospital Universitario La Paz; Servicio de Oncologia
Madrid, 28046
Hospital Universitario Puerta de Hierro; Servicio de Oncologia
Majadahonda, Madrid, 28222
Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
Málaga, 29010
Hospital Universitario Miguel Servet; Servicio Oncologia
Zaragoza, 50009
Germany9 sites
Helios Klinikum Emil von Behring GmbH
Berlin, 14165
Krankenhaus Merheim Lungenklinik
Cologne, 51109
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
Frankfurt, 60488
Asklepios-Fachkliniken Muenchen-Gauting; Onkologie
Gauting, 82131
Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II
Halle, 06120
Thoraxklinik Heidelberg gGmbH
Heidelberg, 69126
Lungenklinik Hemer
Hemer, 58675
Fachklinik für Lungenerkrankungen
Immenhausen, 34376
Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie
Regensburg, 93053
United Kingdom8 sites
Diana Princess of Wales Hosp.
Grimsby, DN33 2BA
University College London Hospital
London, NW1 - 2PG
Royal Free Hospital
London, NW3 2QS
Guys and St Thomas NHS Foundation Trust, Guys Hospital
London, SE1 9RT
St George's Hospital
London, SW17 0QT
Charing Cross Hospital
London, W6 8RF
Christie Hospital NHS Trust
Manchester, M20 4BX
Kings Mill Hospital
Sutton in Ashfield, NG17 4JL
South Korea6 sites
National Cancer Center; Medical Oncology
Gyeonggi-do, 410-769
Seoul National University Bundang Hospital; Hematology Medical Oncology
Gyeonggi-do, 463-707
Seoul National Uni Hospital; Internal Medicine
Seoul, 03080
Yonsei University Severance Hospital; Medical Oncology
Seoul, 120-752
Samsung Medical Center; Gastroenterology
Seoul, 135-710
Seoul St.Mary's Hospital; Medical Oncology
Seoul, 137-807
Poland5 sites
Medical University of Gdansk
Gdansk, 80-952
Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii
Lodz, 93-513
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
Otwock, 05-400
Med.-Polonia Sp. z o.o. NSZOZ
Poznan, 60-693
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
Warsaw, 02-781
Canada4 sites
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Cite de La Sante de Laval; Hemato-Oncologie
Laval, Quebec, H7M 3L9
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
Montreal, Quebec, H3T 1E2
Windsor Regional Cancer Centre
Windsor, Ontario, N8W 2X3
Taiwan4 sites
China Medical University Hospital
Taichung, 40447
National Taiwan Uni Hospital; Internal Medicine
Taipei, 100
Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology
Taipei, 112
Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology
Taoyuan, 333
Argentina3 sites
Instituto Medico Rio Cuarto
Córdoba
COIBA
Provincia de Buenos Aires, B1884BBF
Instituto de Oncología de Rosario
Rosario, S2000KZE
Austria3 sites
Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin
Innsbruck, 6020
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
Salzburg, 5020
Lkh Vöcklabruck; I. Abt. Für Innere Medizin
Vöcklabruck, 4840
Chile3 sites
Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas
Recoleta, 8420383
Sociedad de Investigaciones Medicas Ltda (SIM)
Temuco, 4810469
ONCOCENTRO APYS; Oncología
Viña del Mar, 2520598
Finland3 sites
Helsinki University Central Hospital; Dep. of Pulmonary Medicine
Helsinki, 00290
Oulu University Hospital; Oncology
Oulu, 90029
Tampere University Hospital; Dept of Oncology
Tampere, 33520
Greece3 sites
Uoa Sotiria Hospital; Oncology
Athens, 115 27
University Hospital of Patras Medical Oncology
Pátrai, 265 04
Thermi Clinic; Oncology Clinic
Thermi Thessalonikis, 570 01
Hungary3 sites
Semmelweis Egyetem X; Pulmonologiai Klinika
Budapest, 1083
University of Pecs, I st Dept of Internal Medicine
Pécs, 7624
Tudogyogyintezet Torokbalint
Törökbálint, 2045
Netherlands3 sites
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, 5223 GZ
Catharina Ziekenhuis; Dept of Lung Diseases
Eindhoven, 5623 EJ
Antonius Ziekenhuis; Dept of Lung Diseases
Nieuwegein, 3435 CM
New Zealand3 sites
Auckland city hospital; Auckland Regional Cancer Centre and Blood Service
Auckland, 1023
Dunedin Hospital
Dunedin
Waikato Hospital; Dept of Medical Oncology
Hamilton, 3240
Portugal3 sites
Hospital Geral; Servico de Pneumologia
Coimbra, 3041-801
Hospital Pulido Valente; Servico de Pneumologia
Lisbon, 1796-001
IPO do Porto; Servico de Oncologia Medica
Porto, 4200-072
Russia3 sites
N.N.Burdenko Main Military Clinical Hospital; Oncology Dept
Moscow, 105229
City Clinical Onc.
Saint Petersburg, 198255
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
Samara, 443031
Sweden3 sites
Sahlgrenska Universitetssjukhuset, Lungmedicinkliniken
Gothenburg, 41345
Universitetssjukhuset Linköping; Lungmedicinkliniken
Linköping, 581 85
Karolinska Universitetssjukhuset, Solna; Lung Allergikliniken N10:02
Stockholm, 171 76
Switzerland3 sites
Kantonsspital Baden; Medizinische Klinik, Onkologie
Baden, 5404
HUG; Oncologie
Geneva, 1211
Luzerner Kantonsspital; Medizinische Onkologie
Lucerne, 6004
Thailand3 sites
Chulalongkorn Hospital; Medical Oncology
Bangkok, 10330
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
Bangkok, 10400
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
Bangkok, 10700
Ukraine3 sites
State Medical Academy; Oncology
Dnipropetrovsk, 43102
Karkiv Regional Oncology Center
Kharkiv, 61070
Uzhgorod Nat. University Central Municip Hosp; Onc Center
Uzhhorod, 88000
Serbia2 sites
Clinic for Pulmonology, Clinical Center of Serbia
Belgrade, 11000
Institute for pulmonary diseases of Vojvodina
Kamenitz, 21204
Turkey (Türkiye)2 sites
Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology
Istanbul, 34300
Izmir Suat Seren Chest Diseases and Surgery Research Hospital
Izmir, 35110
Brazil1 site
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, 90035-903
About this study
Official title: A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Being tested
- Atezolizumab, Docetaxel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AtezolizumabDrug
Also called Tecentriq
1200 mg IV infusion on Day 1 of each 21-day cycle
DocetaxelDrug
75 mg/m^2 IV infusion on Day 1 of each 21-day cycle
| Study group | Role | What they receive |
|---|---|---|
| Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody | Experimental | Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. Receives: Drug: Atezolizumab |
| Docetaxel | Active comparator | Docetaxel 75 milligrams per meter square (mg/m^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. Receives: Drug: Docetaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Who Died: PP-ITT
Measured: Baseline until death due to any cause (up to approximately 2.25 years)
Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP
Percentage of participants who died among TC1/2/3 or IC1/2/3 subgroup of PP-ITT were reported. TC1 = presence of discernible programmed death-ligand 1 (PD-L1) staining of any intensity in >/=1% and <5% TCs; TC2: presence of discernible PD-L1 staining of any intensity in >/=5% and <50% TCs; TC3 = presence of discernible PD-L1 staining of any intensity in >/=50% TCs; IC1 = presence of discernible PD-L1 staining of any intensity in ICs covering between >/=1% and <5% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC2 = presence of discernible PD-L1 staining of any intensity in ICs covering between >/=5% and <10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC3 = presence of discernible PD-L1 staining of any intensity in ICs covering >/=10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma.
Measured: Baseline until death due to any cause (up to approximately 2.25 years)
Overall Survival (OS): PP-ITT
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Measured: Baseline until death due to any cause (up to approximately 2.25 years)
OS: TC1/2/3 or IC1/2/3 Subgroup of PP
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Measured: Baseline until death due to any cause (up to approximately 2.25 years)
OS: SP-ITT
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Measured: Baseline until death due to any cause (up to approximately 2.87 years)
OS: TC1/2/3 Or IC1/2/3 Subgroup of SP
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Measured: Baseline until death from any cause (approximately 2.87 years)
OS: TC2/3 or IC2/3 Subgroup of SP
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Measured: Baseline until death due to any cause (up to approximately 2.87 years)
OS: TC3 or IC3 Subgroup of SP
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Measured: Baseline until death due to any cause (up to approximately 2.87 years)
Secondary outcomes (29)
Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT
PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 millimeters (mm), or presence of new lesions.
Measured: Baseline up to PD or Death (up to approximately 2.25 years)
Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP
PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Measured: Baseline up to PD or Death (up to approximately 2.25 years)
Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT
PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Measured: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP
PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Measured: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT
Objective response is defined as a complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than [<] 10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
Measured: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP
Objective response is defined as a CR or PR as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis <10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
Measured: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT
DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
Measured: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP
DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
Measured: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab
Measured: Baseline up to approximately 2.25 years (assessed at predose [Hour {Hr} 0] on Day 1 of Cycles 1, 2, 3, 4, 8, 16, then every 8 cycles up to end of treatment (EOT) [approximately 2.25 years]; 120 days after EOT [approximately 2.25 years] [1 Cycle=21 days])
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Measured: Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days)
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Measured: Predose (Hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8, 16, 24, 32, EOT (approximately 2.25 years); 120 days after EOT (approximately 2.25 years) (1 Cycle=21 days)
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)
TTD in patient-reported lung cancer symptoms (pain in chest or in arm/shoulder, dyspnea, or cough) was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the symptoms. A >/=10-point change in the score perceived by participants was considered as clinically significant. The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years) (1 Cycle = 21 days)
EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items
EORTC QLQ-C30 included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-C30 Questionnaire Score: Functional Subscales
EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-C30 Questionnaire Score: GHS Scale
EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-C30 Questionnaire Score: Symptom Subscale
EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Alopecia
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for alopecia.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Coughing
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for coughing.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Dysphagia
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for dysphagia.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Dyspnea
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for dyspnea.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Hemoptysis
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for hemoptysis.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in arm or shoulder.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Pain in Chest
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in chest.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for peripheral neuropathy.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in other parts.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Sore Mouth
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for sore mouth.
Measured: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
PFS as Determined by Investigator Using RECIST v1.1: SP-ITT
PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Measured: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT
Objective response is defined as a complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than [<] 10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
Measured: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)
DOR as Determined by Investigator Using RECIST v1.1: SP ITT
DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
Measured: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2013 (estimated)
- Study start11 Mar 2014
- Primary completion7 Jul 2016
- Study completion9 Jan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Non-Squamous Non-Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,225 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02008227
- Sponsor's protocol ID
- GO28915
- Other IDs
- 2013-003331-30
- Acronym
- OAK
- Status last verified
- Dec 2019
- First submitted
- 6 Dec 2013
- Last updated
- 20 Dec 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Liu J, Chu C, Yi B, Chen MH. A Max 0-1 Weighted Log-Rank Test for Time-to-Event Data With Random Delayed Treatment Effect. Stat Med. 2026 Oct;45(23-24):e70773. doi: 10.1002/sim.70773.
PubMed 42888494Melchionna R, Di Modugno F, Di Carlo A, D'Ambrosio L, Palermo B, Tocci A, Paolini F, Sperduti I, Campo G, Taje R, Gallina F, Visca P, D'Andrea D, Nistico P. Reciprocal regulation of hMENA and TGF-beta signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. J Immunother Cancer. 2026 Jan 27;14(1):e013098. doi: 10.1136/jitc-2025-013098.
PubMed 41592891Mhatre SK, Machado RJM, Ton TGN, Trinh H, Mazieres J, Rittmeyer A, Bretscher MT. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data. Clin Pharmacol Ther. 2023 Dec;114(6):1313-1322. doi: 10.1002/cpt.3045. Epub 2023 Sep 28.
PubMed 37696652Saal J, Bald T, Eckstein M, Ritter M, Brossart P, Ellinger J, Holzel M, Klumper N. Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial. JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad027. doi: 10.1093/jncics/pkad027.
PubMed 37004206Dong Y, Zhu Y, Zhuo M, Chen X, Xie Y, Duan J, Bai H, Hao S, Yu Z, Yi Y, Guan Y, Yuan J, Xia X, Yi X, Wang J, Wang Z. Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Cancers (Basel). 2022 Nov 17;14(22):5649. doi: 10.3390/cancers14225649.
PubMed 36428744Cortellini A, Ricciuti B, Borghaei H, Naqash AR, D'Alessio A, Fulgenzi CAM, Addeo A, Banna GL, Pinato DJ. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022 Aug 15;128(16):3067-3079. doi: 10.1002/cncr.34348. Epub 2022 Jun 21.
PubMed 35727053Gadgeel S, Hirsch FR, Kerr K, Barlesi F, Park K, Rittmeyer A, Zou W, Bhatia N, Koeppen H, Paul SM, Shames D, Yi J, Matheny C, Ballinger M, McCleland M, Gandara DR. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clin Lung Cancer. 2022 Jan;23(1):21-33. doi: 10.1016/j.cllc.2021.05.007. Epub 2021 May 30.
PubMed 34226144Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, Mendus D, Ballinger M, Rittmeyer A, Peters S. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer. 2021 Mar;9(3):e001882. doi: 10.1136/jitc-2020-001882.
PubMed 33737340Shemesh CS, Chan P, Legrand FA, Shames DS, Das Thakur M, Shi J, Bailey L, Vadhavkar S, He X, Zhang W, Bruno R. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacol Res Perspect. 2020 Dec;8(6):e00685. doi: 10.1002/prp2.685.
PubMed 33241650Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG; imCORE working group of early career investigators. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020 Apr;31(4):525-531. doi: 10.1016/j.annonc.2020.01.006. Epub 2020 Jan 16.
PubMed 32115349Morrissey KM, Marchand M, Patel H, Zhang R, Wu B, Phyllis Chan H, Mecke A, Girish S, Jin JY, Winter HR, Bruno R. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019 Dec;84(6):1257-1267. doi: 10.1007/s00280-019-03954-8. Epub 2019 Sep 21.
PubMed 31542806Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer. 2019 Feb;128:105-112. doi: 10.1016/j.lungcan.2018.12.017. Epub 2018 Dec 19.
PubMed 30642441Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2018 Sep;19(5):441-449.e4. doi: 10.1016/j.cllc.2018.05.011. Epub 2018 May 31.
PubMed 30017645Hida T, Kaji R, Satouchi M, Ikeda N, Horiike A, Nokihara H, Seto T, Kawakami T, Nakagawa S, Kubo T. Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. Clin Lung Cancer. 2018 Jul;19(4):e405-e415. doi: 10.1016/j.cllc.2018.01.004. Epub 2018 Feb 1.
PubMed 29525239Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
PubMed 27979383
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
- ClinicalTrials.gov ID
- NCT02008227
- Acronym / sponsor ID
- OAK / GO28915
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,225 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 11 Mar 2014 (actual)
- Primary completion
- 7 Jul 2016 (actual)
- Study completion
- 9 Jan 2019 (actual)
- First posted
- 11 Dec 2013 (estimated)
- Results
- Posted 2 Jul 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody | Experimental | Drug: AtezolizumabAtezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. |
| Docetaxel | Active comparator | Drug: DocetaxelDocetaxel 75 milligrams per meter square (mg/m^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
- Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Key exclusion criteria (7 listed)
- Known active or untreated central nervous system (CNS) metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Active hepatitis B or hepatitis C
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AtezolizumabAlso: Tecentriq1200 mg IV infusion on Day 1 of each 21-day cycle | Drug | Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody |
| Docetaxel75 mg/m^2 IV infusion on Day 1 of each 21-day cycle | Drug | Docetaxel |
Primary outcome
Percentage of Participants Who Died: PP-ITT
Time frame: Baseline until death due to any cause (up to approximately 2.25 years)
Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP
Time frame: Baseline until death due to any cause (up to approximately 2.25 years)
Percentage of participants who died among TC1/2/3 or IC1/2/3 subgroup of PP-ITT were reported. TC1 = presence of discernible programmed death-ligand 1 (PD-L1) staining of any intensity in >/=1% and <5% TCs; TC2: presence of discernible PD-L1 staining of any intensity in >/=5% and <50% TCs; TC3 = presence of discernible PD-L1 staining of any intensity in >/=50% TCs; IC1 = presence of discernible PD-L1 staining of any intensity in ICs covering between >/=1% and <5% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC2 = presence of discernible PD-L1 staining of any intensity in ICs covering between >/=5% and <10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC3 = presence of discernible PD-L1 staining of any intensity in ICs covering >/=10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma.
Overall Survival (OS): PP-ITT
Time frame: Baseline until death due to any cause (up to approximately 2.25 years)
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC1/2/3 or IC1/2/3 Subgroup of PP
Time frame: Baseline until death due to any cause (up to approximately 2.25 years)
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: SP-ITT
Time frame: Baseline until death due to any cause (up to approximately 2.87 years)
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC1/2/3 Or IC1/2/3 Subgroup of SP
Time frame: Baseline until death from any cause (approximately 2.87 years)
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC2/3 or IC2/3 Subgroup of SP
Time frame: Baseline until death due to any cause (up to approximately 2.87 years)
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC3 or IC3 Subgroup of SP
Time frame: Baseline until death due to any cause (up to approximately 2.87 years)
OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
29 secondary outcomes
Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT
Time frame: Baseline up to PD or Death (up to approximately 2.25 years)
Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP
Time frame: Baseline up to PD or Death (up to approximately 2.25 years)
Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT
Time frame: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP
Time frame: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab
Time frame: Baseline up to approximately 2.25 years (assessed at predose [Hour {Hr} 0] on Day 1 of Cycles 1, 2, 3, 4, 8, 16, then every 8 cycles up to end of treatment (EOT) [approximately 2.25 years]; 120 days after EOT [approximately 2.25 years] [1 Cycle=21 days])
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Time frame: Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days)
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Time frame: Predose (Hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8, 16, 24, 32, EOT (approximately 2.25 years); 120 days after EOT (approximately 2.25 years) (1 Cycle=21 days)
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years) (1 Cycle = 21 days)
EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-C30 Questionnaire Score: Functional Subscales
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-C30 Questionnaire Score: GHS Scale
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-C30 Questionnaire Score: Symptom Subscale
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Alopecia
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Coughing
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Dysphagia
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Dyspnea
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Hemoptysis
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Pain in Chest
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
EORTC QLQ-LC13 Questionnaire Score: Sore Mouth
Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)
PFS as Determined by Investigator Using RECIST v1.1: SP-ITT
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT
Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)
DOR as Determined by Investigator Using RECIST v1.1: SP ITT
Time frame: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42888494Liu J, Chu C, Yi B, Chen MH. A Max 0-1 Weighted Log-Rank Test for Time-to-Event Data With Random Delayed Treatment Effect. Stat Med. 2026 Oct;45(23-24):e70773. doi: 10.1002/sim.70773.
- Derived from this study: PubMed 41592891Melchionna R, Di Modugno F, Di Carlo A, D'Ambrosio L, Palermo B, Tocci A, Paolini F, Sperduti I, Campo G, Taje R, Gallina F, Visca P, D'Andrea D, Nistico P. Reciprocal regulation of hMENA and TGF-beta signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC. J Immunother Cancer. 2026 Jan 27;14(1):e013098. doi: 10.1136/jitc-2025-013098.
- Derived from this study: PubMed 37696652Mhatre SK, Machado RJM, Ton TGN, Trinh H, Mazieres J, Rittmeyer A, Bretscher MT. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data. Clin Pharmacol Ther. 2023 Dec;114(6):1313-1322. doi: 10.1002/cpt.3045. Epub 2023 Sep 28.
- Derived from this study: PubMed 37004206Saal J, Bald T, Eckstein M, Ritter M, Brossart P, Ellinger J, Holzel M, Klumper N. Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial. JNCI Cancer Spectr. 2023 Mar 1;7(2):pkad027. doi: 10.1093/jncics/pkad027.
- Derived from this study: PubMed 36428744Dong Y, Zhu Y, Zhuo M, Chen X, Xie Y, Duan J, Bai H, Hao S, Yu Z, Yi Y, Guan Y, Yuan J, Xia X, Yi X, Wang J, Wang Z. Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Cancers (Basel). 2022 Nov 17;14(22):5649. doi: 10.3390/cancers14225649.
- Derived from this study: PubMed 35727053Cortellini A, Ricciuti B, Borghaei H, Naqash AR, D'Alessio A, Fulgenzi CAM, Addeo A, Banna GL, Pinato DJ. Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022 Aug 15;128(16):3067-3079. doi: 10.1002/cncr.34348. Epub 2022 Jun 21.
- Derived from this study: PubMed 34226144Gadgeel S, Hirsch FR, Kerr K, Barlesi F, Park K, Rittmeyer A, Zou W, Bhatia N, Koeppen H, Paul SM, Shames D, Yi J, Matheny C, Ballinger M, McCleland M, Gandara DR. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clin Lung Cancer. 2022 Jan;23(1):21-33. doi: 10.1016/j.cllc.2021.05.007. Epub 2021 May 30.
- Derived from this study: PubMed 33737340Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, Mendus D, Ballinger M, Rittmeyer A, Peters S. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer. 2021 Mar;9(3):e001882. doi: 10.1136/jitc-2020-001882.
- Derived from this study: PubMed 33241650Shemesh CS, Chan P, Legrand FA, Shames DS, Das Thakur M, Shi J, Bailey L, Vadhavkar S, He X, Zhang W, Bruno R. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacol Res Perspect. 2020 Dec;8(6):e00685. doi: 10.1002/prp2.685.
- Derived from this study: PubMed 32115349Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG; imCORE working group of early career investigators. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020 Apr;31(4):525-531. doi: 10.1016/j.annonc.2020.01.006. Epub 2020 Jan 16.
- Derived from this study: PubMed 31542806Morrissey KM, Marchand M, Patel H, Zhang R, Wu B, Phyllis Chan H, Mecke A, Girish S, Jin JY, Winter HR, Bruno R. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol. 2019 Dec;84(6):1257-1267. doi: 10.1007/s00280-019-03954-8. Epub 2019 Sep 21.
- Derived from this study: PubMed 30642441Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer. 2019 Feb;128:105-112. doi: 10.1016/j.lungcan.2018.12.017. Epub 2018 Dec 19.
Related trials for Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Not yet recruitingPhase 2
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
Active, not recruitingPhase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Non-small Cell Lung Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
208 sites in 31 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Atezolizumab and Docetaxel in people with Non-Squamous Non-Small Cell Lung Cancer, run by Hoffmann-La Roche at 208 sites in 31 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 208 sites in United States, France, Italy, Japan, Spain and 26 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Jul 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Who Died: PP-ITT (time frame: Baseline until death due to any cause (up to approximately 2.25 years)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02008227, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2019.